Reversion of cardiac dysfunction by a novel orally available calcium/calmodulin-dependent protein kinase II inhibitor, RA306, in a genetic model of dilated cardiomyopathy.
Beauverger P, Ozoux ML, Bégis G, Glénat V, Briand V, Philippo MC, Daveu C, Tavares G, Roy S, Corbier A, Briand P, Dorchies O, Bauchet AL, Nicolai E, Duclos O, Tamarelle D, Pruniaux MP, Muslin AJ, Janiak P.
Beauverger P, et al. Among authors: ozoux ml.
Cardiovasc Res. 2020 Feb 1;116(2):329-338. doi: 10.1093/cvr/cvz097.
Cardiovasc Res. 2020.
PMID: 31038167